Vertex Pharmaceuticals Incorporated
US ˙ NasdaqGS ˙ US92532F1003

SecurityVRTX / Vertex Pharmaceuticals Incorporated
InstitutionRathbone Brothers plc
Latest Disclosed Ownership955 shares
Latest Disclosed Value $ 426,445
Rathbone Brothers plc reports 23.23% decrease in ownership of VRTX / Vertex Pharmaceuticals Incorporated

On May 12, 2026 - Rathbone Brothers plc filed a 13F-HR form disclosing ownership of 955 shares of Vertex Pharmaceuticals Incorporated (US:VRTX) valued at $426,446 USD as of March 31, 2026. The entity filed a previous 13F-HR/A on February 6, 2026 disclosing 1,244 shares of Vertex Pharmaceuticals Incorporated. This represents a change in shares of -23.23% during the quarter. The current value of the position is $421,862 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-12 2026-03-31 13F VERTEX PHARMACEUTICAL INC USD0.01 COM 92532F100 955 -289 -23.23 426 -24.33 0.0018
2026-02-06 2025-12-31 13F/A-1 VERTEX PHARMACEUTICAL INC USD0.01 COM 92532F100 1,244 0 0.00 564 15.61 0.0022
2026-01-21 2025-12-31 13F VERTEX PHARMACEUTICAL INC USD0.01 COM 92532F100 1,244 0 564 0.0022
2025-11-13 2025-09-30 13F VERTEX PHARMACEUTICAL INC USD0.01 COM 92532F100 1,244 -7 -0.56 487 -12.41 0.0020
2025-08-07 2025-06-30 13F VERTEX PHARMACEUTICAL INC USD0.01 COM 92532F100 1,251 0 0.00 557 -8.25 0.0024
2025-05-13 2025-03-31 13F VERTEX PHARMACEUTICAL INC USD0.01 COM 92532F100 1,251 -203 -13.96 607 3.59 0.0029
2025-02-13 2024-12-31 13F VERTEX PHARMACEUTICAL INC USD0.01 COM 92532F100 1,454 0 0.00 586 -13.46 0.0028
2024-11-13 2024-09-30 13F VERTEX PHARMACEUTICAL INC USD0.01 COM 92532F100 1,454 355 32.30 676 31.26 0.0034
2024-08-09 2024-06-30 13F VERTEX PHARMACEUTICAL INC USD0.01 COM 92532F100 1,099 -570 -34.15 515 -26.11 0.0028
2024-05-14 2024-03-31 13F VERTEX PHARMACEUTICAL INC USD0.01 COM 92532F100 1,669 179 12.01 698 15.02 0.0040
2024-02-13 2023-12-31 13F VERTEX PHARMACEUTICAL INC USD0.01 COM 92532F100 1,490 227 17.97 606 38.04 0.0039
2023-11-13 2023-09-30 13F VERTEX PHARMACEUTICAL INC USD0.01 COM 92532F100 1,263 1,263 439 0.0032
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.